LINDA AG launches first OTC private-label medicine with ibuprofen
LINDA AG is introducing Ibuprofen 400 mg as the first OTC medicine under its own pharmacy brand across LINDA Premium pharmacies.
Lilly to acquire AtaiBeckley and expand depression pipeline
Lilly plans to acquire AtaiBeckley, adding clinical neuroplastogen programs for treatment-resistant depression to its neuroscience pipeline.
Schwabe takes majority stake in Hydraid
Schwabe Group takes a majority stake in Hydraid, strengthening its position in natural health solutions and functional sports hydration.
Besins acquires UniD to expand pharmatech capabilities
Besins Healthcare acquires Belgium-based UniD Manufacturing to expand long-acting drug delivery and hormone health innovation capabilities.
Vertex to buy Crinetics for about $10 billion
Vertex will acquire Crinetics for about $10 billion, adding PALSONIFY and late-stage endocrine disease assets to its portfolio.
DAT 2026: Final agenda for Munich published
The final agenda for German Pharmacists’ Day 2026 has been published. The event will take place in Munich in September.
Merz visits Sandoz site in Barleben
German Chancellor Friedrich Merz visits Sandoz in Barleben, highlighting medicine supply, value creation and stable policy conditions.
Otsuka completes acquisition of Transcend Therapeutics
Otsuka America has completed its acquisition of Transcend Therapeutics, adding a late-stage PTSD candidate to its CNS pipeline.
Bayer Kultur reviews stARTfestival 2026
Bayer Kultur has closed stARTfestival 2026. Around 30 events combined international artists, dance, performance and talent development.
STADA to acquire Orifarm consumer healthcare portfolio
STADA will acquire 16 VMS brands from Orifarm, expanding its consumer healthcare footprint in Europe, especially Nordics, Belgium and Poland.
Aurobindo USA receives FTC clearance for Lannett acquisition
Aurobindo Pharma USA has received FTC clearance to acquire Lannett. The deal is expected to close before the end of June 2026.
AbbVie to acquire Apogee and expand immunology pipeline
AbbVie plans to acquire Apogee for about $10.9 billion, adding clinical immunology assets for atopic dermatitis and asthma.
Johnson & Johnson invests over $1 billion in Jacksonville vision operations
Johnson & Johnson will invest more than $1 billion in Jacksonville to expand ACUVUE contact lens manufacturing, packaging and distribution.
GSK to acquire Nuvalent in $10.6 billion oncology deal
GSK agreed to buy Nuvalent for $10.6 billion, adding late-stage lung cancer assets and broadening its oncology growth platform.
Germany backs away from variable drug discount plan
Germany will drop a variable discount plan for branded drugs, Reuters reports, after pharmaceutical companies warned of investment cuts.
Established medicines need renewed focus
Christopher Hähner of Good Healthcare Pharma says established medicines need active lifecycle management despite the industry's innovation focus.
Bayer CEO Bill Anderson warns of Germany’s competitiveness gap
Bayer CEO Bill Anderson says high energy costs and bureaucracy put Germany at a disadvantage. He also warns of fertilizer risks linked to Hormuz disruptions.
Boehringer Ingelheim halts planned investment in Germany
Boehringer Ingelheim is halting €900 million in planned investment in Germany for 2027 to 2030, citing policy-related and location factors.
Italy probes Biogen over Tysabri test and market abuse claims
Italy’s AGCM is investigating Biogen over alleged market abuse tied to anti-JCV testing for Tysabri, with potential effects on Sandoz.
Biogen completes acquisition of Apellis Pharmaceuticals
Biogen has completed its acquisition of Apellis. The deal adds SYFOVRE and EMPAVELI and is positioned to support Biogen’s nephrology expansion.